U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Supreme Court Tests Federal Reserve Independence Amid Trump’s Bid to Fire Lisa Cook 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Federal Reserve Faces Subpoena Delay Amid Investigation Into Chair Jerome Powell 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
On Monday, a U.S. appeals court ruled in favor of 3M, E.I. du Pont de Nemours and Co, and other manufacturers of "forever chemicals." The court rejected a lower court's ruling, allowing approximately 11.8 million Ohio residents to sue the companies.
Reuters noted that the ruling relieves considerable legal pressure placed on the chemical manufacturers to settle the plaintiffs' claims.
Court Ruling Questions Class Action Suit's Validity
According to Yahoo, Lead plaintiff Kevin Hardwick's complaint against the manufacturers faced scrutiny from the court. The appeals court found his complaint to be overly broad and lacking evidence that the per- and polyfluoroalkyl substances (PFAS) detected in his body could be directly attributed to the defendants.
The court emphasized that the complaint targeted the collective actions of the companies rather than individual responsibility. Notably, the case involved just 10 out of thousands of companies involved in PFAS manufacturing.
The lower court's approval of the class action suit has been vacated, and the court instructed the dismissal of Hardwick's lawsuit. The lawsuit aimed to hold the companies accountable for the health impacts of PFAS exposure and sought to establish a fund to monitor Ohio residents.
Additionally, Hardwick's request for the companies to fund studies on the health effects of PFAS was denied. These forever chemicals, commonly found in consumer products, have been linked to cancer and other diseases.
Robert Bilott, attorney for Hardwick, expressed disappointment with the court's decision. He stated that it contradicts what is known about the history of PFAS manufacturing in the United States. Bilott's legal team is currently evaluating whether to appeal the ruling further.
The Persistence and Prevalence of Forever Chemicals
PFAS substances earned the nickname "forever chemicals" due to their resistance to breaking down in nature or in the human body. The growing number of lawsuits filed against 3M, DuPont, and other manufacturers in recent years reflect concerns over alleged PFAS contamination.
In June, 3M agreed to pay $10.3 billion to settle hundreds of claims regarding public drinking water pollution caused by PFAS. Furthermore, Chemours Co, DuPont de Nemours Inc, and Corteva reached a similar settlement worth $1.19 billion with U.S. water providers.
Photo: 3M News Center
